Bavarian Nordic A/S

BAVA

DK0015998017

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 16/07/2024 pm IST			5-day change	1st Jan Change
182.7 ^DKK	+3.63%		-1.35%	+2.96%

01/07	Bavarian Nordic Turns DKK1 Billion Facility into Sustainability-linked Loan	MT
28/06	Nordic Stocks Rose Friday; Millicom International Cellular Climbed Highest	DJ

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

January 16, 2023 at 02:02 pm IST

Bavarian Nordic A/S provided revenue guidance for Fiscal Year 2022 latest. For the period, company expects Revenue to be DKK 2,800 Million – DKK 3,000 million than the previous DKK 1,100 million – DKK 1,400 million.

Latest news about Bavarian Nordic A/S

Bavarian Nordic Turns DKK1 Billion Facility into Sustainability-linked Loan	01/07	MT
Nordic Stocks Rose Friday; Millicom International Cellular Climbed Highest	28/06	DJ
Bavarian Nordic Donates Mpox Vaccine to Combat African Outbreak	28/06	MT
Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa	28/06	CI
Congo authorities approve mpox vaccines to try to contain outbreak	27/06	RE
Congo authorities approve mpox vaccines to try to contain outbreak	26/06	RE
Bavarian Nordic Files EU Application for Chikungunya Vaccine Candidate	26/06	MT
Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema	26/06	CI
Bavarian Nordic Wraps Up US FDA's Biologics License Application for Chikungunya Vaccine Candidate	18/06	MT
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate	17/06	CI
High-risk health workers can get routine Ebola vaccine, Gavi says	13/06	RE
High-risk health workers can get routine Ebola vaccine, says Gavi	13/06	RE
Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine	31/05	MT
Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children	30/05	MT
Bavarian Nordic A/S and Coalition for Epidemic Preparedness Innovations Partners to Advance Mpox Vaccination in Africa	30/05	CI
Bavarian Nordic’s Medical Chief to Step Down by May-end	21/05	MT
Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer	21/05	CI
Transcript : Bavarian Nordic A/S, Q1 2024 Earnings Call, May 08, 2024	08/05
Bavarian Nordic A/S commences an Equity Buyback Plan, under the authorization approved on April 16, 2024.	08/05	CI
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024	08/05	CI
Bavarian Nordic A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Bavarian Nordic Books EUR65 Million Order for Smallpox Vaccine	30/04	MT
Bavarian Nordic A/S Receives EUR 65 Million Contract to Supply Smallpox Vaccines for EU Strategic Reserve	30/04	CI
Bavarian Nordic Starts US Rolling Submission Process for Chikungunya Vaccine Candidate	29/04	MT
Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate	29/04	CI

Chart Bavarian Nordic A/S

Duration

Period

More charts

Company Profile

Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases. Net sales by revenue source are divided between sales of products (97.8%) and services (2.2%). Net sales are distributed geographically as follows: the United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8%), Switzerland ( 1.5%), Sweden (1%), Chile (0.9%), Taiwan (0.8%), the United Kingdom (0.6%), Hong Kong (0.2%), Saudi Arabia (0.1%), and others (4.9%).

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Bavarian Nordic A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

182.7 DKK

Average target price

263.2 DKK

Spread / Average Target

+44.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAVARIAN NORDIC A/S	+2.96%	200.68Cr
ELI LILLY AND COMPANY	+61.53%	86TCr
NOVO NORDISK A/S	+38.95%	63TCr
JOHNSON & JOHNSON	-3.66%	36TCr
MERCK & CO., INC.	+15.06%	32TCr
ABBVIE INC.	+9.18%	30TCr
ROCHE HOLDING AG	+5.89%	23TCr
NOVARTIS AG	+16.53%	23TCr
AMGEN INC.	+15.67%	18TCr
PFIZER, INC.	+2.47%	16TCr

Other Pharmaceuticals